Single-dose pharmacokinetics and tolerability of alendronate 35-and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I
LM Ward, AE Denker, A Porras… - The Journal of …, 2005 - academic.oup.com
Context: Alendronate (ALN) is a bisphosphonate compound that can be administered orally
and has potential use in pediatric osteoporotic conditions. Objective: The objective was to …
and has potential use in pediatric osteoporotic conditions. Objective: The objective was to …
[PDF][PDF] Single-Dose Pharmacokinetics and Tolerability of Alendronate 35-and 70-Milligram Tablets in Children and Adolescents with Osteogenesis Imperfecta Type I
LM Ward, AE Denker, A Porras, S Shugarts, W Kline… - Context - researchgate.net
Objective: The objective was to evaluate the pharmacokinetics and single-dose tolerability of
ALN in children with osteogenesis imperfecta. Design: ALN was administered iv and orally …
ALN in children with osteogenesis imperfecta. Design: ALN was administered iv and orally …
[引用][C] Single-dose pharmacokinetics and tolerability of alendronate 35-and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I
LM WARD, AE DENKER, P DEUTSCH… - The Journal of …, 2005 - pascal-francis.inist.fr
Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in
children and adolescents with osteogenesis imperfecta type I CNRS Inist Pascal-Francis CNRS …
children and adolescents with osteogenesis imperfecta type I CNRS Inist Pascal-Francis CNRS …
Single-dose pharmacokinetics and tolerability of alendronate 35-and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I
LM Ward, AE Denker, A Porras… - The Journal of …, 2005 - pubmed.ncbi.nlm.nih.gov
Context Alendronate (ALN) is a bisphosphonate compound that can be administered orally
and has potential use in pediatric osteoporotic conditions. Objective The objective was to …
and has potential use in pediatric osteoporotic conditions. Objective The objective was to …
[PDF][PDF] Single-Dose Pharmacokinetics and Tolerability of Alendronate 35-and 70-Milligram Tablets in Children and Adolescents with Osteogenesis Imperfecta Type I
LM Ward, AE Denker, A Porras, S Shugarts… - … - publicationslist.org.s3.amazonaws …
Objective: The objective was to evaluate the pharmacokinetics and single-dose tolerability of
ALN in children with osteogenesis imperfecta. Design: ALN was administered iv and orally …
ALN in children with osteogenesis imperfecta. Design: ALN was administered iv and orally …
Single-dose pharmacokinetics and tolerability of alendronate 35-and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I.
LM Ward, AE Denker, A Porras, S Shugarts… - The Journal of …, 2005 - europepmc.org
Objective The objective was to evaluate the pharmacokinetics and single-dose tolerability of
ALN in children with osteogenesis imperfecta. Design ALN was administered iv and orally in …
ALN in children with osteogenesis imperfecta. Design ALN was administered iv and orally in …
[PDF][PDF] Single-Dose Pharmacokinetics and Tolerability of Alendronate 35-and 70-Milligram Tablets in Children and Adolescents with Osteogenesis Imperfecta Type I
LM Ward, AE Denker, A Porras, S Shugarts, W Kline… - Context - Citeseer
Objective: The objective was to evaluate the pharmacokinetics and single-dose tolerability of
ALN in children with osteogenesis imperfecta. Design: ALN was administered iv and orally …
ALN in children with osteogenesis imperfecta. Design: ALN was administered iv and orally …